FiercePharma  10 hrs ago  Comment 
Novartis has launched plenty of large-scale multiple sclerosis studies. But its newest one is different. The latest, dubbed elevateMS, allows participants to contribute no matter where they are by using their smartphones and an app developed for...
Cellular News  Aug 21  Comment 
EAST HANOVER, N.J. , Aug. Novartis announced today the launch of a mobile research study for people with multiple sclerosis (MS) that collects data via their smartphone, without the need for clinic visits. The study, Evaluation of Evidence from...
FiercePharma  Aug 21  Comment 
Cancer patient David Mitchell is so concerned about the potentially high price of CAR-T treatments that he requested a meeting with Joe Jimenez, CEO of Novartis, as the company works to establish a price for its upcoming product in this new class.
The Hindu Business Line  Aug 21  Comment 
Novartis is taking aim at the drug-resistant malaria—a growing global problem—by launching clinical trials of the first new antimalarial medicine for many years in nine countries across Africa and As...
FierceBiotech  Aug 17  Comment 
UCSF cardiovascular research leader Shaun Coughlin will join the Novartis Institutes for BioMedical Research, Novo Nordisk's China GM was promoted to lead the company's corporate operations, and troubled Teva lost a key executive to small biotech...
FierceBiotech  Aug 17  Comment 
The director of UCSF's Cardiovascular Research Institute—Shaun Coughlin, M.D., Ph.D.—has joined the ranks of senior academics heading to drugmaker Novartis.
SeekingAlpha  Aug 16  Comment 
FiercePharma  Aug 15  Comment 
When Novartis launched its heart failure drug Entresto two years ago at a list price of $4,600 a year, it was in for a tough fight against cheap generics. Now the tide is finally turning in Novartis’ favor.


Fuerralz? That's marvelously good to know.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki